Format

Send to

Choose Destination
Thorac Cancer. 2018 Jan;9(1):193-196. doi: 10.1111/1759-7714.12557. Epub 2017 Nov 13.

Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

Author information

1
Department of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
2
Department of Pathology, Sasebo City General Hospital, Nagasaki, Japan.
3
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
4
Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.

Abstract

Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohistochemical analysis revealed few PD-1+ immune cells and regulatory T cells in the tumor, in addition to predominant infiltration of CD8+ cells and macrophages. Our findings suggest that the presence of a small number of PD-1+ immune cells and regulatory T cells should be investigated as candidate therapeutic biomarkers.

KEYWORDS:

Immunotherapy; programmed death-1; regulatory T cells

PMID:
29131510
PMCID:
PMC5754285
DOI:
10.1111/1759-7714.12557
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center